Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Nov;21(5):316-9.
doi: 10.1007/s00345-003-0368-6. Epub 2003 Oct 9.

Transdermal testosterone delivery: testosterone patch and gel

Affiliations
Review

Transdermal testosterone delivery: testosterone patch and gel

Louis J G Gooren et al. World J Urol. 2003 Nov.

Abstract

Testosterone replacement treatment is usually life-long. Fortunately, testosterone administration is relatively safe and until the age of 50 years few side effects are noted with normal doses of testosterone. After the age of 50 years when prostate disease becomes more prevalent, shorter-acting testosterone preparations, allowing a fast reduction of circulating testosterone levels, may be an advantage. Testosterone has an impact on sexual and non-sexual behaviour and short-acting testosterone preparations may be better suited for the initiation of long-term administration allowing the monitoring of behavioural effects. Testosterone can be delivered to the circulation through the intact skin, both genital and non-genital. Transdermal administration delivers testosterone at a controlled rate into the systemic circulation, avoiding hepatic first pass and reproducing the diurnal rhythm of testosterone secretion and without the peak and trough levels observed with the use of the traditional long-acting testosterone injections. In conclusion, both the testosterone patch and testosterone gel are valuable contributions to androgen replacement treatment meeting the requirements specified for testosterone replacement treatment.

PubMed Disclaimer

References

    1. J Clin Endocrinol Metab. 2003 Jun;88(6):2673-81 - PubMed
    1. Clin Endocrinol (Oxf). 2002 May;56(5):637-41 - PubMed
    1. Clin Ther. 1998 Mar-Apr;20(2):299-306 - PubMed
    1. Clin Endocrinol (Oxf). 1999 May;50(5):629-35 - PubMed
    1. BJU Int. 2003 Jan;91(1):69-74 - PubMed

LinkOut - more resources